Intellia Therapeutics (NTLA) Share-based Compensation (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Share-based Compensation data on file, last reported at $13.5 million in Q1 2026.

• Quarterly Share-based Compensation fell 38.28% year-over-year to $13.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.9 million (down 49.37% YoY) and the FY2025 annual result came in at $80.2 million, down 48.0% from the prior year.
• Share-based Compensation fell to $13.5 million in Q1 2026 per NTLA's latest filing, from $16.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $40.9 million in Q2 2024 and bottomed at $13.5 million in Q1 2026.
• The 5-year median for Share-based Compensation is $25.2 million (2022), against an average of $27.8 million.
• The widest annual swing landed in 2022, when Share-based Compensation jumped 187.84%; it then tumbled 57.75% in 2025.
• Tracing NTLA's Share-based Compensation over 5 years: stood at $24.6 million in 2022, then soared by 42.3% to $35.0 million in 2023, then gained by 13.05% to $39.6 million in 2024, then plunged by 57.75% to $16.7 million in 2025, then dropped by 19.48% to $13.5 million in 2026.
• Per Business Quant, the three latest NTLA Share-based Compensation figures stand at $13.5 million (Q1 2026), $16.7 million (Q4 2025), and $19.6 million (Q3 2025).

Peer Comparison